atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change – Yahoo Finance
atai Impact is committed to advancing education, expanding access and supporting the wider ecosystem of mental health care
NEW YORK and BERLIN, Oct. 19, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company, today announced the launch of its new philanthropic program, atai Impact, in line with atai Life Sciences’ vision, to heal mental health disorders so that everyone, everywhere can live a more fulfilled life.
atai Impact has been developed to harness the power of innovative mental health approaches for positive social change, committed to advancing education, expanding access and supporting the wider ecosystem.
Its establishment is based on atai Life Sciences’ position that, while a for-profit model is the swiftest and most robust means of unlocking new modalities for patients in need, this model alone cannot address all aspects of the escalating global mental crisis.
Therefore, atai Life Sciences believes having harmonization among commercial and non-profit entities is the ideal way forward. The initial focus of atai Impact will be on the psychedelic sector, given its emerging potential in tackling the growing mental health crisis.
Supporting and collaborating with nonprofits and institutions that share its vision of healing mental health disorders, atai Impact will operate across three central pillars:
Education: to help destigmatize mental health, promote better understanding of the potential of psychedelics in mental health care, and foster the next generation of neuro-innovators.
Access: to support equal access to innovative and effective mental health support, for everyone, everywhere, regardless of geography or demographics.
Ecosystem: to contribute to the sustainability of diverse stakeholder communities and environments, including indigenous resources.
“The launch of atai Impact is a very proud moment for everyone at atai Life Sciences and for me, personally. While we believe a for-profit model is the best way to get new treatments to patients in need, not all aspects of the global mental health crisis can be effectively addressed by this model alone,” said Florian Brand, Chief Executive Officer and Co-founder of atai Life Sciences.
“I’ve been moved by the huge volume of support, internally and externally, that we have had in bringing atai Impact to life and by the commitment of so many of our staff, founders and investors who’ve already joined me in contributing a portion of their own company equity to this important program. We are in active discussions with multiple stakeholders towards meaningful initiatives that we believe can help make a real difference to the future of psychedelic medicine and mental health care worldwide.”
The atai Impact program will be initially funded by 1% of the gross proceeds from atai Life Sciences’ June 2021 Initial Public Offering (NASDAQ) and founders’ contributions. In addition, atai Life Sciences has created a Volunteer Paid Time Off Policy, equal to 1% of employees’ time, and is working with the Equity for Impact initiative to encourage employees and investors to donate a portion of their equity to charitable endeavors.
About atai Life Sciences
atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. atai’s business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal mental health disorders. atai’s mission is to bridge the gap between what the mental healthcare system currently provides and what patients need. atai has offices in New York, London, and Berlin. For more information, please visit www.atai.life.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this press release (including without limitation, the atai Impact program and any other future philanthropic endeavors by atai) that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors discussed under the caption “Risk Factors” in atai’s prospectus pursuant to Rule 424(b) filed with the U.S. Securities and Exchange Commission (“SEC”) on June 21, 2021, as such factors may be updated from time to time in atai’s other filings with the SEC. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.
Photo by cottonbro from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced that its wholly-owned subsidiary Pasithea Clinics has partnered with ZEN Healthcare to offer intravenous (IV) ketamine therapy to patients suffering from treatment-resistant mental health issues. The treatment will be offered in London’s Knightsbridge district
The company’s oral COVID-19 treatment looks like a dud in the mild-to-moderate COVID-19 setting.
Atea Pharmaceuticals said Tuesday its Merck-rivaling antiviral Covid pill failed in a midstage test, leading AVIR stock to crash.
Photo by Towfiqu barbhuiya on Unsplash Broad agreement in the world of science can be a rarity. However, one thing that public health leaders active in the fight against COVID-19 can agree on, is the urgent need for oral, pill-based treatments that are effective at halting disease progression, can get — and keep — people out of the hospital and can reduce mortality. One key group of COVID-19 patients who are in desperate need of treatment options are those moderately severe patients in hospital
Anavex Life Sciences and Affimed both sport unique drug development platforms that could be worth billions.
The company applied in April for Food and Drug Administration approval to sell the new product. Now that process could take a bit more time.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) has announced Day 90 data for the first patient from the Phase 1/2 trial of VX-880 for type 1 diabetes (T1D). VX-880 is an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy. The patient, who had suffered five potentially life-threatening hypoglycemic (low blood sugar) episodes in the year before the therapy, was injected with synthetic insulin-producing cells. After 90 days, the patient’s new cells
Biogen and Ionis’ approach to Lou Gehrig’s disease flopped over the weekend, leading IONS stock to collapse to a five-year low Monday.
Failing to enroll in Medicare can lead to some steep penalties, and that’s just as true for Medicare Part D, which covers prescription drugs. Eight in 10 Medicare beneficiaries were not aware of the late enrollment penalty for Part D, according to a survey of more than 1,000 people from MedicareAdvantage.com. The penalty applies to people who do not have “creditable drug coverage” for 63 days.
Public-health experts hope that a Covid-19 pill could be an affordable, convenient tool to reduce the human cost of the virus.
Edesa Biotech Inc (NASDAQ: EDSA) is trading higher Tuesday after the company announced additional results from the Phase 2 part of the ongoing Phase 2/3 study of EB05 in COVID-19. Edesa reported that EB05 demonstrated mortality reductions in multiple patient groups beyond the initial findings. The company said it believes EB05 regulates the overactive and dysfunctional immune response associated with Acute Respiratory Distress Syndrome, which is the leading cause of death in COVID-19 patients. “
A recent survey found that most business executives support the vaccine and testing mandates, but have concerns over their implementation.
U.S. regulators ‘will start moving [booster] recommendations to earlier ages,’ predicts Albert Bourla.
Curious what activities may be associated with higher COVID-19 transmission? Here’s what data suggests.
These dividend stocks provide sustainable and growing dividends, which are nearly triple the S&P 500’s yield.
Artificial intelligence is coming for the $11 trillion doctor industry, and it could change how you and your doctor interact for decades to come
The FDA rejected Revance Therapeutics’ frown lines treatment, depressing RVNC stock which fell to an 18-month low on Monday.
Data: CDC; Note: Data represents 30% of Americans across 16 jurisdictions: Alabama, Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Idaho, Louisiana, Massachusetts, Michigan, Nebraska, New Mexico, New York City, Seattle/King County, Wash., Utah and Wisconsin; Chart: Danielle Alberti/AxiosEven vaccinated Americans who are 80 or older are at higher risk of dying from the coronavirus than anyone — vaccinated or not — under the age of 50, according to CDC data.Why it matters: The vaccine
Shares of Avadel Pharmaceuticals (NASDAQ: AVDL) are down 14% as of 1:29 p.m. EDT today after the Food and Drug Administration said it would need more time than originally thought to review FT218 — Avadel’s candidate to treat narcolepsy. After accepting a company’s approval filing, the FDA provides applicants with a date known as the Prescription Drug User Fee Amendments date — or PDUFA date. In some instances — like that of Avadel’s FT218 — the agency misses its target.
Is Pfizer stock a buy after the CDC recommended Covid booster shots for people age 65 and older, and otherwise vulnerable Americans?